




CME FOUNDATION OF INDIA



**NOVEL THERAPY TO
TREAT CKD ANEMIA IN INDIA**

EVENT REPORT

About Workshop

The **CME Foundation of India** organized an academic workshop on **Novel Therapy to Treat CKD Anemia in India** on 24th January 2026 at ESIC Super Speciality Hospital, Sanathnagar, Hyderabad. The session aimed to address the unmet clinical needs in the management of anemia associated with chronic kidney disease (CKD) and to explore emerging therapeutic approaches in this domain.

The workshop was attended by physicians and nephrologists from ESIC Hospital and surrounding centers. The session by **Dr. Lalithambika Devi B. N.** covered multiple aspects of CKD anemia management, such as understanding the growing challenge in CKD anemia, limitations of current therapies, desidustat as a novel therapy in CKD management, its mechanism, and practical integration in clinical practice.

Date: 24th January 2026

Venue: ESIC Super Speciality Hospital, Sanathnagar, Hyderabad

No. of participants: 19

Agenda

Date: 24th January 2026

Time: 11:15 p.m. to 12:15 p.m.

Topics	Speaker	Timings
Registration		11:15 a.m. – 11:25 a.m.
Welcome Note		11:25 a.m. – 11:30 a.m.
Novel Therapy to Treat CKD Anemia in India	Dr. Lalithambika Devi B. N. M.B.B.S., D.N.B. (Medicine), D.N.B. (Nephrology)	11:30 a.m. – 12:10 p.m.
Vote of Thanks		12:10 p.m. – 12:15 p.m.

Summary of the Novel Therapy to Treat CKD Anemia in India

The Growing Challenge of CKD-Related Anemia in India

Dr. Lalithambika Devi B.N. opened the session by drawing attention to the substantial burden of anemia associated with chronic kidney disease (CKD) in India. She emphasized its significant impact on patient outcomes, quality of life, and healthcare expenditure. She explained that CKD-related anemia is a complex, multifactorial condition driven by factors such as iron deficiency, chronic inflammation, and impaired erythropoietin production. Dr. Lalithambika Devi B.N. noted that the interplay of these mechanisms complicates anemia management and highlighted the pressing need for innovative treatment approaches beyond conventional options.

Gaps and Challenges in Current Anemia Management

The discussion then turned to currently available therapies, including erythropoiesis-stimulating agents (ESAs) and iron supplementation. Dr. Lalithambika Devi B.N. outlined several limitations of these treatments, such as variable effectiveness, potential safety issues, and restricted access within the Indian healthcare setting. She explained that these challenges often lead to inadequate hemoglobin control, frequent dose modifications, and reduced patient adherence, thereby leaving important gaps in the management of CKD-related anemia.

Desidustat: A Novel Therapeutic Approach

A key focus of the workshop was Desidustat, a novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Dr. Lalithambika Devi B.N. described how Desidustat stimulates endogenous erythropoietin production, improves iron utilization, and reduces hepcidin levels. By targeting multiple underlying pathways of CKD-related anemia, Desidustat offers a potentially safer and more convenient oral alternative to traditional ESA therapy, reducing reliance on injections and potentially enhancing patient adherence.

Evidence Supporting Desidustat Use

Dr. Lalithambika Devi B.N. reviewed key clinical trial data demonstrating Desidustat's ability to effectively increase and maintain stable hemoglobin levels across varied patient populations. He also highlighted its favorable safety and tolerability profile. Additionally, real-world clinical experience was shared, supporting the effectiveness of Desidustat in both dialysis-dependent and non-dialysis CKD patients.

Practical Insights into Clinical Practice

The session concluded with practical insights on patient selection, dosing regimens, monitoring requirements, and key considerations for integrating Desidustat into routine CKD anemia management. Participants discussed actionable strategies to optimize treatment, improve adherence, and enhance patient outcomes, underscoring a patient-centric approach to contemporary anemia care.

At the end of the Conclave, the CME Foundation of India extended its sincere gratitude to the speaker and delegates for attending the conclave and acknowledged Zydus Lifesciences Ltd., the industry partner, for their valuable support and contribution to the success of the Conclave.

Snapshots of Success

Venue



Lecture on Novel Therapy to Treat CKD Anemia in India





Developed by:

CME FOUNDATION OF INDIA

Building "A" Sahney Business Centre, 27 Kirol Road, Vidyavihar (W), Mumbai - 400086
Tel: +91 22 61798600 | Website: www.cmefi.co.in